Inmune Bio, Inc.
Ebstrocel™
RDEB
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on Ebstrocel™ for RDEB is in focus around Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“The Company also intends to use the MHRA feedback to inform future interactions with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) with additional filings planned in late 2026 or early 2027, subject to ”